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Abstract
Background Cardiogoniometry (CGM) is a novel elec-
trocardiac method utilising computer-assisted three-
dimensional information on cardiac potentials.
Objective To investigate the potential of CGM in dis-
criminating non-ST-segment elevation acute coronary
syndrome (NSTE-ACS) and relevant coronary stenosis upon
hospital admission by prospectively comparing its sensitiv-
ity, specificity and accuracy against those of a single troponin
test and a 12-lead ECG performed on admission
Design A multicenter prospective observational trial.
Setting Eight interventional cardiac centres in Germany.
Patients A cohort of 216 patients (mean age 67 years,
34.7 % female) who presented with acute chest pain or
dyspnoea without ST-segment elevation and were sched-
uled for coronary angiography within 72 h of admission.
Intervention Pre-angiography screening by CGM, tropo-
nin test, 12-lead ECG
Main outcome measures ECG, troponin and CGM on
admission compared with final diagnosis of NSTE-ACS or
relevant diameter stenosis C70 % verified by an indepen-
dent review board and an angiographic core laboratory.
Results NSTE-ACS was finally confirmed in 162 cases,
whereas the remaining 54 cases without proof of NSTE-
ACS served as controls. Diagnostic sensitivity for NSTE-
ACS was 28, 50 and 69 % and specificity 78, 96 and 54 %
for first ECG, serial troponin and first CGM, respectively.
Accuracy was 40, 62 and 65 %. The sensitivity of the tests
to detect relevant coronary stenosis (n = 126) was 32, 53
and 74 %, respectively. The sensitivity of CGM to detect
NSTE-ACS (65 %) or relevant stenosis (71 %) was high
even in patients with normal troponin and ECG.
On behalf of the CGM@ACS trialists
R. To¨lg (&)  G. Richardt
Herzzentrum, Segeberger Kliniken GmbH,
Am Kurpark 1, 23795 Bad Segeberg, Germany
e-mail: ralph.toelg@segebergerkliniken.de
U. Zeymer
Med. Klinik B, Herzzentrum Ludwigshafen,
Ludwigshafen, Germany
R. Birkemeyer








Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
W. Bocksch
Innere Medizin III, Medizinische Klinik Und Poliklinik,
Tu¨bingen, Germany
S. Schneider
Stiftung Institut fu¨r Herzinfarktforschung an der Universita¨t
Heidelberg, Ludwigshafen, Germany
C. Hamm
Herz- und Thoraxzentrum, Kerckhoff Klinik GmbH,
Bad Nauheim, Germany
123
Clin Res Cardiol (2012) 101:727–736
DOI 10.1007/s00392-012-0452-2
Conclusions CGM can detect NSTE-ACS at first medical
contact. CGM in conjunction with traditional markers,
12-lead ECG and troponin may effectively aid early deci-
sion making in patients presenting with acute chest pain.
Keywords Chest pain  Emergency  Infarction 
Ischaemia  Patient management  Triage 
Vector cardiography
Introduction
Acute coronary syndrome (ACS) comprises a spectrum of
presentations including unstable angina pectoris and myo-
cardial infarctions which are further subdivided into
infarctions with and without ST-segment elevations. In the
majority of cases, the pathology underlying ACS results
from erosion or rupture of a thin fibrous cap of a lipid-rich
atherosclerotic plaque, leading to thrombus formation [1].
Patients with unstable angina exhibit ischaemic symptoms,
although biomarkers reveal no evidence of myocardial
necrosis [2]. Patients with clinical symptoms and elevated
cardiac biomarkers may present with ST-segment elevation
myocardial infarction (STEMI) or non-ST-segment eleva-
tion myocardial infarction (NSTEMI). Current guidelines
recommend early reperfusion therapy for STEMI [3, 4] and
an early invasive strategy for NSTEMI [5]. A fast, simple
and reliable diagnostic tool is critical for optimal man-
agement of ACS patients [2, 6]. While a STEMI can be
rapidly detected by ECG in most instances, NSTEMI and
unstable angina, subsumed as NSTE-ACS, may not show
diagnostically relevant changes on the ECG or elevations
of cardiac markers at first medical contact [7]. This
dilemma is responsible for a significant consumption of
time and healthcare resources [8]. There is an unmet need
for a practical, cost-effective and accurate diagnostic tool
capable of detecting patients with NSTE-ACS or even
relevant stenoses at first medical contact. Acknowledging
that a chest pain unit can improve long-term outcome [21]
by prompt identification and treatment of patients with an
ACS this is even more requested.
Cardiogoniometry (CGM) is a novel electrodiagnostic
method utilising computer-assisted three-dimensional
information on cardiac potentials. It was introduced by
Sanz et al. [9] and has been adjusted for detection of cor-
onary artery disease (CAD) in recent years by Schu¨pbach
and Hu¨bner [10, 11]. In a prospective cohort of 332 sub-
jects undergoing coronary angiography, the diagnostic
accuracy of CGM was 71 % for detecting[50 % stenoses
of the coronary arteries and thereby significantly better
than that of a 12-lead ECG (p \ 0.003) [10]. Birkemeyer
et al. [18] prospectively evaluated the accuracy of CGM
versus cardiac magnetic resonance imaging (MRI) in 40
patients. CGM reached a high accuracy of 83 %, a sensi-
tivity of 70 % and a specificity of 95 %. In summary, there
are CGM studies of approximately 2,000 patients in vari-
ous settings versus different reference standards available.
In a review based on meta analyses, the sensitivity of CGM
has been described to be around 73 % and the specificity
around 84 %, respectively, to detect CAD, myocardial
ischaemia or structural myocardial damages [12]. We
therefore sought to investigate the potential of ECG, tro-




This was a prospective observational trial to compare the
sensitivity, specificity and accuracy of (not high-sensitive)
troponin test, 12-lead ECG and CGM for detecting NSTE-
ACS and/or relevant stenoses (C70 %) on admission. Final
confirmation of the diagnosis was post hoc and based on all
clinical information, including serial measurements, but the
reviewers were blinded to the CGM results.
Patient selection
In the prospective CGM@ACS (CardioGonioMetry for
early detection of acute myocardial ischaemia in Acute
Coronary Syndromes) study, patients admitted to one of the
eight participating centres with acute chest pain and/or
dyspnea were eligible for inclusion if they received an
ECG and troponin test on admission and were scheduled
for coronary angiography within 72 h. Exclusion criteria
were: ST-segment elevation myocardial infarction
(STEMI), cardiogenic shock, presence of significant car-
diac ectopic beats, pacemaker, tachycardia [150 beats/
min, bundle branch block and/or atrial fibrillation. All
patients had to provide informed consent before inclusion
and their data had to be entered anonymously in an online
database. 216 patients were finally eligible for analysis.
Validation of the clinical diagnosis
Two independent, blinded investigators (study review
board) evaluated the clinical diagnosis of the patients based
on the data in the online database: patient history, cardio-
vascular risk profile and symptoms at admission. The fol-
lowing parameters were available for all patients included
into the study: ECG, two-dimensional and M-Mode echo-
cardiography, troponin, CK, CK-MB, creatinine and NT-
proBNP. Serial recordings of ECG and serial biomarker
results were made available whenever applicable by
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clinical routine. The coronary angiography reports were
provided by the institutions, and the investigators had
access to the original angiographies. Based on this post hoc
validation on the patient’s entire clinical course, including
coronary angiography, patients were assigned to two clin-
ical groups blinded by the results of CGM (Fig. 1): The
first group, NSTE-ACS, subsumed NSTEMI and unstable
angina. NSTEMI was defined as patients presenting with
acute chest pain without persistent ST-segment elevation
according to the definition provided by Thygesen et al.
[13], but with elevation of myocardial markers such as
troponin or CK-MB showing a typical rising and falling
pattern. Unstable angina was defined according to Cannon
and Braunwald [14] in patients with negative biomarkers.
The second group consisted of all patients with either
cardiac symptoms, but no ACS, or extracardiac symptoms;
these patients served as the control group. Thus, the control
group included patients with existing, but stable coronary
heart disease with no acute ischaemic symptoms and
patients with myocarditis or pericarditis, cardiomyopathy,
valvular heart disease, hypertensive crisis, pleuritis, pneu-
monia, aortic syndrome, gastrointestinal disorders, such as
gastritis or peptic ulcer, or musculoskeletal disorders, such
as discopathy, costochondritis or muscular hardening.
All coronary angiograms were reviewed by an inde-
pendent core laboratory (Institut fu¨r Herzinfarktforschung
Ruhr, Essen, Germany) that graded coronary stenosis by
quantitative coronary analysis. A stenosis of at least 70 %
in diameter in a major coronary artery was regarded as
relevant.
The trial protocol and informed consent was approved by
an independent ethical review board (Ethikkommission der
Landesa¨rztekammer Rheinland-Pfalz, Mainz, Germany).
Test validation
We compared the results of the immediate CGM, first ECG
at rest and first troponin test taken at the moment of
admission to the hospital with the final diagnosis estab-
lished by the review board. If indicated, serial troponin
tests were collected and included in the comparison. In this
highly selected but well diagnosed cohort, we evaluated the
true positive and false negative test results obtained in the





















































(non-ACS / extracardiac) 
true positive / 
false negative ? 
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false positive ? 
exclusion of patients 
according protocol criteria 
2./serial troponin
Fig. 1 Flowchart of the 216 eligible patients analysed per protocol.
The final diagnosis was validated post hoc by independent reviewers,
who based their judgment on all clinical information including but not
limited to serial measurements of biomarkers and ECG recordings.
They were blinded to the CGM recordings. The patients were
assigned to the NSTE-ACS group (n = 162) or control group
(n = 54). The review board’s assignment validated how well the
results of the first ECG, first or serial troponin and first CGM at the
time of admission discriminated NSTE-ACS against controls
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positive test results used to detect patients of the control
group, respectively (Fig. 1). Secondly, comparable analysis
was performed with regard to relevant coronary stenoses.
Principles of cardiogoniometry
The trigonometric principles of CGM have been published
in detail elsewhere [9–12]. Briefly, four electrodes define
two planes perpendicular to each other. Vectorial addition
of the potentials measured between three electrodes in each
plane yields a vector that corresponds to the projection of
the heart vector into this plane. Using the vector projec-
tions in the two orthogonal planes, the heart vector can be
reconstructed for every millisecond. The vector orientation
indicates the direction and the vector length the intensity of
the electrical field generated by the heart.
Three mutually orthogonal projections X, Y and Z are
calculated trigonometrically. This Cartesian coordinate
system (XYZ) is roughly orientated according to the anat-
omy of the heart and its orientation in the chest, which is
greatly advantageous for visualising spatial de- and repo-
larisation and produces an immediate cardiac interpretation
of the recorded vectorial information (Fig. 2). The X-axis
has an anteroposterior orientation (values with positive
signs have a posterior location). The Y-axis has a left-
oblique-sagittal baso-apical orientation (values with posi-
tive signs point to the apex and those with negative signs to
the base of the heart). The main plane (oblique sagittal
plane) is defined by the X- and Y-axes. The Z-axis is per-
pendicular to the two other planes (values with negative
signs point up). The frontal plane is defined by the Y- and
Z-axes. The plane defined by the X- and Z-axes is also a
sagittal plane, which is perpendicular to the oblique sagittal
and frontal planes and separates the apical and basal por-
tions of the heart.
CGM differs from conventional seven-lead Frank vec-
torcardiography in two essential respects. Firstly, CGM is
recorded with five leads (4 electrodes and 1 ground)
without intercalated resistor networks (uncorrected tech-
nique). The geometrical electrode placement in an
orthogonal system avoids the distortions associated with
vectorcardiography techniques. In CGM, the electrode
position and the trigonometrical constructions lead to a
Fig. 2 Principles of cardiogoniometry, a The four signal electrodes
are placed on the thorax: at point 1 (green), equivalent to point V4 of
Wilson, in the fifth intercostal space in the midclavicular line; at point
2 (white) sagittal to electrode 1 on the back (point V8 of Wilson); at
point 3 (yellow) perpendicularly above electrode 1 at 0.7 times the
distance between points 1 and 2; at point 4 (red) to the right of point 3
at the same distance as between points 1 and 3. The fifth electrode is
ground and can be attached somewhere above the right hip. The leads
are defined as: 4-2 D (dorsal), 4-1 A (anterior), 2-1 I (inferior), 4-3 Ho
(horizontal), 3-1 Ve (vertical). b Points 4–2–1 define the oblique
sagittal plane (OSP) (red); points 4–3–1, the frontal plane (yellow).
The third plane (blue) is orthogonal to the two other planes and
contains point 3; it is the sagittal plane perpendicular to the OSP.
Projection X is orientated in an anterodorsal direction and lies in the
OSP and the sagittal plane perpendicular to the OSP. Projection Y is
orientated in a baso-apical direction and lies in the OSP (4–2–1) and
the frontal plane (4–3–1). Projection Z is orientated in a supero-
inferior direction relative to the OSP and lies in the frontal plane
(4–3–1) and the sagittal plane perpendicular to the OSP. c Vector-
loops can be calculated within a Cartesian coordinate system using X,
Y and Z coordinates of the heart vector at each ms recording. Note the
R-loops (blue) and T-loops (green) of 12 heart cycles and maximum
vectors of both loops (red). The maximum vectors are calculated on
the median loops (with kind permission from Springer Science ?
Business Media from [11], figure number 1)
b
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mathematically correct orthogonality of XYZ projections.
Secondly, CGM projection planes are not aligned with the
body planes but rotated to approximately match the ana-
tomical orientation of the heart similar to the short axis
scan of an MRI.
A total of 350 parameters can be extracted from the
CGM data fully automatically and divided into main
classes: Angles consisted of longitude and latitude angles
of the P, R and T-loops, in particular, the angle of the
maximum vectors and at further defined positions in the
loops and angles between the maximum vectors of the P, R
and T-loops. The amplitude class comprised the minima/
maxima and amplitude ratios of P, R and ST/T segments.
Shapes and eccentricities were used to describe the P, R
and T-loops. Potential distributions covered the P, R and
ST/T-loops in octants. Velocities were classified as abso-
lute values and ratios of the P, R and T-loops. In addition,
all parameters were classified according to variability
(adapted from [11]). As CAD may alter the surface
potential of the global cardiac activity in different ways,
depending on the affected area of the myocardium, a
combination of independent penalising variables has been
compiled to gender and rhythm specific sets and is used in
the standard CGM method since 2008. Hu¨bner et al. proved
that specific CGM parameters are significant and suitable
for detecting predefined CAD categories and the system-
atically computed algorithm in the standard CGM method
derived from a diagnostic set of stenosis pattern-specific,
parallel and equally ranked parameters enables global CAD
detection. Although not every parameter is useful for every
CAD category, the overall parameter set inside the standard
CGM algorithm is independent of coronary stenosis
localisation and distribution or ischaemia pattern [11]. All
parameters of a set must be in their reference range to
define a score of zero (normal CGM). For each parameter
outside of its reference range a negative score point is
counted [10, 11]. Any negative score point reflects a
pathologic (positive) CGM. In summary, CGM captures
the temporospatial informations and their beat-to-beat
variance breaking them down to several relevant and
measurable parameters that can be taken as reference. In
contrast, conventional ECG only takes into account the
cardiac electricity at 12 lead points over one heart cycle.
Cardiogoniometry measurements
The CGM measurements were obtained by placing five
leads on the supine patient and using commercially avail-
able hard- and software (Cardiologic Explorer, enverdis,
Jena, Germany). During the 12-s recording, the patient was
asked to perform shallow breathing to keep thoracic
excursions to a minimum.
Interpreting a CGM finding
When all parameters recorded on a patient are within
normal range, a score of zero is produced, i.e., the CGM is
negative. If any parameter is out of range, the score is
below zero, thus defining a pathological or ‘‘positive’’
CGM. The immediate, automatically produced finding was
registered as the CGM diagnosis, which was entered in the
electronic case record form. Albeit the phrase ‘‘score’’ is
used, the CGM produces a dichotomic result of ‘‘positive’’
or ‘‘negative’’ CGM. The numerical value of the score
below zero does not reflect a measure of extent or severity
of ischaemia.
Troponin and ECG
Troponin was measured as T or I according to the local
practice of each site. No highly sensitive troponin was
used. A value within the reference limit of the respective
test kit was regarded as negative, whilst a value above the
upper limit of normal was regarded as positive. With
respect to serial troponin results, a test was regarded
positive if at least one of the measurements was positive.
Conversely, a serial troponin testing had to be regarded
negative if every single test at different time points was
negative. An ECG with persistent or transient ST-segment,
new horizontal or down-sloping ST depression C0.05 mV
in two contiguous leads and/or T inversion C0.1 mV in two
contiguous leads with prominent R-wave or R/S ratio [1
was regarded as indicative of acute myocardial ischaemia
and therefore registered as positive; all other cases were
registered as negative[13].
Statistical analysis
Data are presented as absolute numbers, percentage or
medians as appropriate. Categorical values and the pre-
dictive values were compared by Chi-square test or Fish-
er’s exact test in smaller sample sizes. Continuous
variables were compared using the two-tailed Wilcoxon
rank sum test. The McNemar test was performed to com-
pare sensitivities, specificities and the diagnostic accuracy
of CGM ECG, and Troponin. p values \0.05 were con-
sidered significant. All statistical analyses were performed
using SAS statistical analysis software 9.1 (Cary, North
Carolina).
Results
In the total cohort of 216 patients, NSTE-ACS was
detected in 162 patients, the remaining 54 patients were
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diagnosed to have cardiac disease, but not ACS (n = 20),
or to have chest pain of extracardiac origin (n = 34) after
post hoc verification of the diagnosis by the study review
board.
The baseline characteristics of the patients in each group
are shown in Table 1.
Patients presenting with NSTE-ACS were on average
[10 years older than the controls and had a higher rate of
Table 1 Baseline characteristics and angiographic details
NSTE-ACS Control p value
n 162 54
Age (years) 69.5 (59.0–75.0) 59.0 (51.0–70.0) \0.001
Female 32.7 % 40.7 % 0.28
History
Diabetes 28.4 % 14.8 % \0.05
Hyperlipidemia 67.9 % 46.3 % \0.01
Arterial hypertension 88.9 % 72.2 % \0.01
Family history of CAD 27.2 % 16.7 % 0.12
Renal insufficiency 10.5 % 1.9 % \0.05
Smoker 27.8 % 35.2 % 0.30
Previous MI 27.8 % 9.3 % \0.01
Previous CABG 16.7 % 0 % \0.01
Previous PCI 42.0 % 16.7 % \0.001
Previous Stroke 6.2 % 5.6 % 0.87
Peripheral artery disease 4.9 % 0 % 0.10
Clinical presentation at admission
Duration of symptoms (h:min) 10:56 (2:48–50:47) 6:31 (2:20–41:09) 0.29
Chest pain 99.4 % 100 % 0.56
Dyspnea 16.7 % 7.4 % 0.09
Systolic blood pressure (mmHg) 140 (122–160) 140 (127–150) 0.42
Diastolic blood pressure (mmHg) 80 (70–89) 78 (70–80) 0.42
Heart rate (bpm) 71 (63–81) 67 (62–75) 0.15
Killip class 1 ? 2 98.8 % 100 % 1.00
Medication at admission
ASA 71.6 % 68.5 % 0.67
Thienopyridines 24.1 % 14.9 % 0.15
Anticoagulation 18.6 % 18.5 % 1.00
Betablocker 60.5 % 51.9 % 0.26
Statins 42.6 % 29.6 % 0.09
ACE inhibitors or ARB or renin inhibitors 53.1 % 48.1 % 0.53
Angiographic details (core lab)
Door-to-needle time (h:min) 9:00 (3:27–24:28) 20:30 (4:49–27:31) \0.05
No CAD detected 6.9 % 85.2 % \0.0001
1-coronary vessel disease 32.1 % 14.8 % \0.05
2- and 3- coronary vessel disease 61.0 % 0 % \0.0001
Stenosis C70 % 80.3 % 0 % \0.0001
Impaired TIMI flow (\3) 45.3 % 0 % \0.0001
PCI performed 60.4 % 0 % \0.0001
EF \ 40 % 4.3 % 2.9 % 1.00
EF [ 55 % 70.5 % 91.4 % \0.05
Values in percent or median with interquartile range in brackets. Groups NSTE-ACS and control (patients with non-ACS or extracardiac disease)
as defined in the text under methods
MI myocardial infarction, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, CAD coronary artery disease, ASA acetyl
salicylic acid, ACE angiotensin converting enzyme, ARB Angiotensin receptor blocker, EF ejection fraction
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diabetes mellitus (28.4 %). Cardiovascular risk factors like
hyperlipidemia, arterial hypertension, family history were
more common in NSTE-ACS patients. However, smoking
was equally present in both groups. A previous history of
coronary and peripheral artery disease was more often
present in NSTE-ACS patients, while prior cerebrovascular
events were equally distributed in both groups.
Patients who later turned out to have NSTE-ACS had a
longer history of symptoms prior to hospital admission than
the control group, however, this was not significant. In
contrast, the time from admission to coronary angiography
(door-to-needle time) was significantly shorter in NSTE-
ACS patients. The clinical presentation and haemody-
namics of patients with NSTE-ACS were similar to those
of the control group, although there tended to be more
concomitant dyspnea in the NSTE-ACS group.
Both groups did not differ in their medication at
admission, with a tendency towards a higher use of statins
in the NSTE-ACS group. The control group also showed a
high intake of acetyl salicylic acid (ASA; 68.5 %), beta-
blockers (51.9 %) and blockers of the renin–aldosterone–
angiotensin system (48.1 %), suggesting the presence of
cardiovascular disease. The use of thienopyridines
(14.9 %) in the control group was in line with the rate of
previous PCI (16.7 %), as shown in Table 1.
The angiographic details of the core laboratory analysis
are given in Table 1.
The diagnostic yield of the different methods in
detecting NSTE-ACS versus control and in detecting rel-
evant coronary stenoses (C70 % diameter) is shown in
Table 2.
In our cohort of patients presenting with acute chest
pain, half (n = 106) had a negative ECG and a negative
troponin. In this subgroup, CGM revealed a sensitivity of
65 % and accuracy of 66 % in detecting NSTE-ACS and a
sensitivity of 71 % and accuracy of 63 % in detecting
patients with significant coronary stenoses in the coronary
angiogram (Table 3).
Discussion
CGM is a novel electrodiagnostic and vectorcardiographic
tool proven to detect myocardial ischaemia and CAD [9–
12]. The classic vectorcardiography, a forerunner of CGM,
could not be implemented into routine clinical practice
because it was too difficult to record and interpret. As a
major advancement over the old method, state-of-the-art
CGM fully automatically generates a simple and readily
available diagnosis based on a combination of temporal
and spatial parameters and their variabilities [11]. Thus,
CGM delivers more cardio-electric information than a
conventional 12-lead ECG.
The principal finding of this study is that CGM proved
more sensitivity in detecting NSTE-ACS and relevant
coronary stenosis than conventional ECG or a non-high-
sensitive troponin as a screening method performed at first
medical contact. The major limitations of the well-estab-
lished troponin test are that it is dependent on time-relevant
Table 2 Diagnostic yield of
method in detecting patients
with NSTE-ACS and with
relevant coronary stenoses
Serial troponin reflects any
troponin from first up to third
measurement, if indicated
PPV positive predictive value,
NPV negative predictive value
* p \ 0.001 compared to CGM
 p = 0.001 compared to CGM
 p = 0.002 compared to CGM
# Not significantly different
(p [ 0.05) compared to CGM
ECG First troponin Serial troponin CGM
Detection of NSTE-ACS
Sensitivity 28 % (45/162)* 34 % (55/162)* 50 % (81/162)* 69 % (111/162)
Specificity 78 % (42/54) 98 % (53/54)* 96 % (52/54)* 54 % (29/54)
PPV 79 % (45/57)# 98 % (55/56) 98 % (81/83)* 82 % (111/136)
NPV 26 % (42/159)# 33 % (53/160)# 39 % (52/133)# 36 % (29/80)
Accuracy 40 % (87/216)* 50 % (108/216)* 62 % (133/216)# 65 % (140/216)
Detection of relevant coronary stenoses
Sensitivity 32 % (40/126)* 53 % (67/126)* 74 % (93/126)
Specificity 80 % (68/85)* 81 % (69/85)* 51 % (43/85)
PPV 70 % (40/57)# 81 % (67/83)# 69 % (93/135)
NPV 44 % (68/154)# 54 % (69/128)# 57 % (43/76)
Accuracy 51 % (108/211) 64 % (136/211)# 64 % (136/211)
Table 3 Value of CGM in patients with negative ECG and negative
serial troponin (n = 106)
NSTE-ACS Stenosis C70 %
Sensitivity 65 % (42/65) 71 % (34/48)
Specificity 59 % (24/41) 58 % (31/53)
PPV 71 % (46/59) 61 % (34/56)
NPV 51 % (24/47) 68 % (31/45)
Accuracy 66 % (70/106) 63 % (65/101)
All test evaluations refer to first measurement or recording
PPV positive predictive value, NPV negative predictive value
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protein release kinetics and the fact that, by definition,
patients with unstable angina cannot be diagnosed by tro-
ponin. Using conventional assays, the sensitivity of tro-
ponin T for myocardial infarction increases from 25–65 %
at hospital admission to 59–90 % after 2–6 h [15–17] and
reaches almost 100 % after 6–12 h [15, 16]. These num-
bers are somewhat lower at admission when troponin I is
used, but almost similar to troponin T later on [15–17]. As
our cohort not only comprised patients with myocardial
infarction but also patients with unstable angina, the sen-
sitivity of the troponin test could, by definition, maximally
approach the ratio of infarction patients. On the other hand,
the subgroup of NSTEMI is defined by elevation of myo-
cardial markers, and false positive troponin due to other
causes is very rare. Therefore, the positive predictive value
of troponin has to be high, which only means if there is a
positive troponin there is a very high chance for the diag-
nosis of NSTE-ACS. Notably, the negative predictive
values of troponin and CGM are almost at the same level,
so the chance to detect a true ‘‘healthy’’ subject is com-
parable. Hence, the CGM tool produced a high sensitivity
and accuracy for the early discrimination of NSTE-ACS in
the overall cohort. Moreover, CGM results were acquired
and available immediately at the time of admission and
their sensitivity did not show any time dependency. CGM
should neither challenge the role and clinical importance of
cardiac markers like troponin, nor does it provide any
information on outcome so far, but with its sensitivity for
NSTE-ACS it could be a complementary diagnostic tool in
the first assessment of patients, especially in early pre-
senters after chest pain, as the first ECG and troponin at
admission showed a very poor sensitivity of 28 and 34 %,
respectively. Undoubtedly, this does not necessarily mean
that all positive CGM should be answered by an immediate
coronary angiogram but could at least focus the physicians’
attention especially in the case of a normal ECG and nor-
mal troponin at admission. Overall, performance of CGM
was at least superior to conventional 12-lead ECG. Of
course, a significantly higher sensitivity is contrasted by a
significantly lower specificity of CGM compared to ECG,
but CGM shows higher positive and negative predictive
values and a better accuracy than ECG.
In our study setting, where clinical decision making was
blinded to the results of the CGM recording, we observed
that an average delay of between 9 and 24 h elapsed before
coronary angiography and intervention, even in the group
presenting with NSTE-ACS. This ‘‘early invasive strategy’’
consumed significant clinical resources before final therapy
was initiated. Of course, the prolonged door-to-needle time
might also have been due to purely logistical reasons like
admission in the late afternoon or evening with no need for
an emergent catheter lab procedure. We do not want to
question the standard of care afforded by serial troponin
and ECG recordings; nevertheless, CGM can indeed speed
up decision making or help to triage patients into chest pain
units at least in pre-hospital setting where troponin tests
may not be available. Finally, the combined use of a
positive CGM and/or a positive troponin test would
increase sensitivity for NSTE-ACS to 83 % in cohorts like
ours (Fig. 3).
In this real-life scenario, it is striking that barely half of
the patients (n = 106) scheduled for coronary angiography
based on the clinical suspicion of ACS had a negative ECG
and/or a negative troponin test at first medical contact,
although final diagnosis of ACS was retrospectively con-
firmed in almost three quarters of the cohort.
no. of correctly classified pts. 
correct positive (% sensitivity) 
correct negative (% specificity) 
all correct (% accuracy) 
28% 34% 49% 69% 83% 
78% 98% 96% 54% 54% 
40% 50% 62% 65% 76% 
Fig. 3 Numbers of correctly
positively classified patients out
of 162 patients with NSTE-ACS
based on the first ECG, the first
troponin, all consecutive (serial)
troponin measurements, the first
CGM and a combination of the
first CGM and first troponin
results are shown as dark-grey
bars (percentage reflects
sensitivity). The numbers of
correctly negatively classified
patients in the 54 controls are
shown in light-grey bars
(percentage reflects specificity).
The numbers for all 216 patients
correctly screened (positive and
negative) are represented by
medium-grey bars (percentage
reflects accuracy)
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In the subgroup of patients with no abnormalities on
initial ECG or troponin test, CGM maintained a consis-
tently high sensitivity of 65 and 71 % for detecting NSTE-
ACS and relevant coronary stenoses C70 % in diameter,
respectively. Proposing an algorithm, where patients would
undergo an early invasive strategy, (1) if at least troponin
or ECG is positive and (2) only if both are negative
(n = 106 in this setting), then CGM would add for decision
making, so one would have detected additional 42 patients
with NSTE-ACS by positive CGM out of this latter group
(2) (number needed to treat = 2.5). Conversely, 17 patients
of these 106 would have undergone an early coronary
angiography but without final confirmation of NSTE-ACS
(number needed to harm = 6.2).
Based on these findings, CGM may be used as a com-
plementary tool to the tests currently recommended by the
guidelines to early discriminate patients with ACSs from
patients with non-cardiac chest pain. This advantage would
be especially pertinent to outpatient settings.
In our study cohort, CGM’s specificity proved lower
than that of ECG and troponin, which might have par-
tially been because CGM algorithms are calibrated to
detect ischaemia along with myocardial scars and struc-
tural myocardial lesions. Accordingly, the algorithms do
not discriminate acute ischaemia and chronic disease
from prior coronary events. Also, there was a certain
prevalence of patients with a previous history of myo-
cardial infarction and coronary interventions in the
subgroup of patients who were not classified with NSTE-
ACS retrospectively. Birkemeyer et al. [18] prospectively
evaluated the accuracy of CGM versus stress cardiac
MRI, considered the non-invasive gold standard of
ischaemia diagnosis. In their unselected cohort of 40
patients, CGM findings were compared against patho-
logical perfusion and/or the presence of late enhancement
(20 patients in total) during cardiac MRI. CGM achieved
a total accuracy of 83 %, i.e., a sensitivity of 70 % and a
specificity of 95 %, whilst its positive predictive value
was 93 % [18]. These findings underscore the hypothesis
that the moderately lower specificity within the
CGM@ACS trial was mainly caused by the high preva-
lence of stable CAD and structural myocardial lesions in
the control cohort.
The major limitation of the study was that we inves-
tigated a highly selected cohort of patients with chest pain
who underwent an early invasive treatment strategy. We
therefore might have a higher pre-test probability for
NSTE-ACS patients resulting in a larger number of
patients in the final NSTE-ACS group and fewer patients
in the control group. This presumption would be in line
with the high rate of patients showing a history of CAD
such as previous myocardial infarction or previous re-
vascularisation procedures as shown in Table 1. Even the
control group comprises a cohort of patients with relevant
CAD or prior myocardial damage—nearly one-sixth of
them had had a previous PCI and nearly one-tenth a
previous myocardial infarction (Table 1). Therefore, our
patient population is not representative of patients with
chest pain seen in an outpatient scenario. Secondly, the
broader use of highly sensitive cardiac troponin—com-
pared to that used in this study—would detect more
NSTEMIs [19, 22, 23]. As these next-generation assays
can measure up to tenfold lower troponin concentrations
than conventional assays [20], we might have obtained
higher sensitivity levels if we had used such assays in this
study cohort. Novel biomarkers for early diagnosis of
ACS like fatty acid-binding protein [24], ischaemia-
modified-albumin [25] or copeptin [26] may be promis-
ing, but they could not yet demonstrate incremental value
especially over high-sensitive troponin. Thirdly, interpre-
tation by the independent review board was solely based
on written documentation and written assessment of the
patient’s clinical presentation and not on a direct exami-
nation or interrogation. Last, the sample size of this study
was still low, so a validation of these findings in larger
collectives or a more general population is needed. The
data should be therefore interpreted as hypothesis gener-
ating but not proof of additional value of CGM in the
routine chest pain unit care so far.
In conclusion, CGM is a novel, easy-to-use electrodi-
agnostic method that can help screen patients with acute
chest pain at first medical contact. In cohorts presenting
with chest pain, CGM demonstrated high diagnostic sen-
sitivity and accuracy in detecting patients with NSTE-ACS
or relevant coronary stenoses. Given CGM’s comparably
high sensitivity and accuracy in cases where both troponin
and ECG are negative, it may provide added benefit as a
diagnostic tool in the early detection of ACSs.
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